Jennifer Keiser
16
1
1
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.4% vs industry average
31%
5 trials in Phase 3/4
64%
9 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita
Role: lead
Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini
Role: lead
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Role: lead
Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Role: lead
Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura
Role: lead
Co-administration of IVM and ALB in School-based Deworming in Uganda
Role: lead
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Role: lead
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
Role: lead
Efficacy of Ivermectin-albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura
Role: lead
Efficacy and Safety of IVM/ALB Co-administration
Role: lead
Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Role: lead
Efficacy and Safety of MOX/ALB Co-administration
Role: lead
Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm
Role: lead
Albendazole Dose Finding and Pharmacokinetics in Children and Adults
Role: lead
Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm
Role: lead
Efficacy and Safety of a Multi-dose Regimen of Mebendazole Against Hookworm in Children
Role: lead
All 16 trials loaded